Dr Faith Howard

All publications

Journal articles

• Kwan A, Howard F, Winder N, Atkinson E, Jailani A, Patel PB, Allen R, Ottewell PD, Shaw GC, Conner J , Wilson C et al (2022) Macrophage delivered HSV1716 is active against triple negative breast cancer. Future Pharmacology, 2(4), 444-459.
• Howard FHN, Kwan A, Winder N, Mughal A, Collado-Rojas C & Muthana M (2022) Understanding immune responses to viruses—do underlying Th1/Th2 cell biases predict outcome?. Viruses, 14(7).
• Howard F, Conner J, Danson S & Muthana M (2022) Inconsistencies in modeling the efficacy of the oncolytic virus HSV1716 reveal potential predictive biomarkers for tolerability. Frontiers in Molecular Biosciences, 9.
• Howard FHN, Al‐Janabi H, Patel P, Cox K, Smith E, Vadakekolathu J, Pockley AG, Conner J, Nohl JF, Allwood DA , Collado‐Rojas C et al (2022) Nanobugs as drugs: bacterial derived nanomagnets enhance tumor targeting and oncolytic activity of HSV‐1 virus. Small. View this article in WRRO
• Howard F & Muthana M (2020) Designer nanocarriers for navigating the systemic delivery of oncolytic viruses. Nanomedicine, 15(1), 93-110.
• Lefley D, Howard F, Arshad F, Bradbury S, Brown H, Tulotta C, Eyre R, Alférez D, Wilkinson JM, Holen I , Clarke RB et al (2019) Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts. Breast Cancer Research, 21(1). View this article in WRRO
• Iscaro A, Howard NF & Muthana M (2019) Nanoparticles: Properties and Applications in Cancer Immunotherapy. Current Pharmaceutical Design, 25(17), 1962-1979.
• Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter-Howard F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury S et al (2019) Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. Clinical Cancer Research, 25(9), 2769-2782. View this article in WRRO
• Holen I, Whitworth J, Nutter F, Evans A, Brown HK, Lefley DV, Barbaric I, Jones M & Ottewell PD (2017) Erratum to: Loss of plakoglobin promotes cell-cell contact, increased invasion and breast cancer cell dissemination in vivo.. Breast Cancer Research, 19.
• Burhan I, Furini G, Lortat-Jacob H, Atobatele AG, Scarpellini A, Schroeder N, Atkinson J, Maamra M, Nutter FH, Watson P , Vinciguerra M et al (2016) Interplay between transglutaminases and heparan sulphate in progressive renal scarring. Scientific Reports, 6(1). View this article in WRRO
• Holen I, Walker M, Nutter F, Fowles A, Evans CA, Eaton CL & Ottewell PD (2016) Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. Clinical & Experimental Metastasis, 33(3), 211-224. View this article in WRRO
• Holen I, Nutter F, Wilkinson JM, Evans CA, Avgoustou P & Ottewell PD (2015) Human breast cancer bone metastasis in vitro and in vivo: a novel 3D model system for studies of tumour cell-bone cell interactions. Clinical & Experimental Metastasis, 32(7), 689-702. View this article in WRRO
• Nutter F, Holen I, Brown HK, Cross SS, Evans CA, Walker M, Coleman RE, Westbrook JA, Selby PJ, Brown JE & Ottewell PD (2014) Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocrine-Related Cancer, 21(2), 327-341.
• Rogers TL, Wind N, Hughes R, Nutter F, Brown HK, Vasiliadou I, Ottewell PD & Holen I (2013) Macrophages as potential targets for zoledronic acid outside the skeleton—evidence from in vitro and in vivo models. Cellular Oncology, 36(6), 505-514.
• Nutter F, Khwaja A & Haylor J (2012) Seliciclib Inhibits Renal Hypertrophy but Not Fibrosis in the Rat following Subtotal Nephrectomy. Nephron Experimental Nephrology, 122(3-4), 114-122.
• Holen I, Whitworth J, Nutter F, Evans A, Brown HK, Lefley DV, Barbaric I, Jones M & Ottewell PD (2012) Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo. Breast Cancer Research, 14(3). View this article in WRRO
• Haylor J, Schroeder J, Wagner B, Nutter F, Jestin G, Idée J-M & Morcos S (2012) Skin Gadolinium Following Use of MR Contrast Agents in a Rat Model of Nephrogenic Systemic Fibrosis. Radiology, 263(1), 107-116.
• Ottewell PD, Whitworth J, Cross SS, Nutter FH & Holen I (2011) P2-01-20: Reduced Plakoglobin Expression Increases the Metastatic Potential of Breast Cancer Cells.. Poster Session Abstracts.
• Haylor J, Dencausse A, Vickers M, Nutter F, Jestin G, Slater D, Idee J-M & Morcos S (2010) Nephrogenic Gadolinium Biodistribution and Skin Cellularity Following a Single Injection of Omniscan in the Rat. Investigative Radiology, 45(9), 507-512.
• Nutter FH, Haylor JL & Khwaja A () Inhibiting ERK Activation with CI-1040 Leads to Compensatory Upregulation of Alternate MAPKs and Plasminogen Activator Inhibitor-1 following Subtotal Nephrectomy with No Impact on Kidney Fibrosis. PLOS ONE, 10(9), e0137321-e0137321. View this article in WRRO
• Wilson C, Nutter F, Brown H, Coleman R & Holen I () Effects of the female hormone inhibin-A in vivo: potential contribution to the antitumour effect of Zoledronic acid. Bone Abstracts.

Chapters

• Nutter Howard FH, Iscaro A & Muthana M (2022) Oncolytic viral particle delivery, Systemic Drug Delivery Strategies (pp. 211-230). Elsevier

Conference proceedings papers

• AL-Janabi H, Conner J, Howard F, Hunt S, Taher Z, Staniland S & Muthana M (2019) Abstract LB-188: Breast cancer immunotherapy using magnetized HSV1716. Immunology
• AL-Janabi H, Conner J, Howard F, Hunt S, Taher Z, Staniland S & Muthana M (2019) Abstract LB-188: Breast cancer immunotherapy using magnetized HSV1716. Immunology